Relmada Therapeutics Announces Presentation of NDV-01 Phase 2 Data at the Society for Urologic Oncology
Relmada Therapeutics (NASDAQ:RLMD) was upgraded by analysts at Mizuho from a "neutral" rating to an "outperform" rating. They now have a $10.00 price target on the stock.
Relmada Therapeutics GAAP EPS of -$0.30 [Seeking Alpha]
Relmada Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 13, 2025
Relmada Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants